0001209191-23-020291.txt : 20230321 0001209191-23-020291.hdr.sgml : 20230321 20230321164436 ACCESSION NUMBER: 0001209191-23-020291 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230320 FILED AS OF DATE: 20230321 DATE AS OF CHANGE: 20230321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Al-Wakeel Yasir B. CENTRAL INDEX KEY: 0001650691 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 23750191 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-20 0 0001287098 MAXCYTE, INC. MXCT 0001650691 Al-Wakeel Yasir B. C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 1 0 0 0 0 Stock Option (right to buy) 4.19 2023-03-20 4 A 0 40000 0.00 A 2033-03-19 Common Stock 40000 40000 D This grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. 23,333 of the shares underlying this option vested on March 20, 2023 and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. /s/ Brian F. Leaf, Attorney-in-Fact 2023-03-21